Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.97 |
| ▸ | DRD2 | P14416 | 1/20 | 0.97 |
| ▸ | PTGES | O14684 | 9/20 | 0.84 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.62 |
| ▸ | CDK2 | P24941 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lonazolac SCHEMBL287156 | 1.00 | KDM4E (0.97) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| Lonazolac SCHEMBL25221 | 0.99 | KDM4E (1.00) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL11245260 | 0.93 | KDM4E (0.90) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL11166545 | 0.93 | KDM4E (0.90) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL10877279 | 0.90 | KDM4E (0.83) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL10407060 | 0.89 | KDM4E (1.00) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL12608902 | 0.88 | KDM4E (0.81) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL3475488 | 0.88 | KDM4E (0.81) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| Lonazolac SCHEMBL10577835 | 0.87 | PTGES (1.00) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL11258042 | 0.87 | KDM4E (0.79) | KDM4EDRD2PTGESALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-3752201-A1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-12-23 | — | — | EP | disclosed |
| US-9023889-B2 | Use of ascorbic acid derivatives for the functionalization of matrices | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| EP-1860158-B1 | Particles comprising a substrate and an anion-binding layer | MERCK PATENT GMBH (DE) | 2013-12-04 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7914893-B2 | Particles comprising an anion-binding layer containing anion-forming organic active compounds, and method of making and using thereof | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100167936-A1 | USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES | MERCK PATENT GESELLSCHAFT (DE) | 2010-07-01 | — | — | US | disclosed |
| EP-2049075-A2 | USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES | Merck Patent GmbH (DE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017346-A2 | USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES | MERCK PATENT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| US-20070275244-A1 | Particles | MERCK PATENT GMBH | 2007-11-29 | — | — | US | disclosed |
| EP-1860158-A2 | Particles comprising a substrate and an anion-binding layer | MERCK PATENT GmbH (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100167936-A1 | USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES | PROC, TTPA, COX6C | KDM4E 4007/4885DRD2 1441/4885PTGES 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.